Verve Therapeutics (VERV) News Today → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free VERV Stock Alerts $5.36 +0.15 (+2.88%) (As of 04:15 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 2:12 AM | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Receives $33.00 Consensus Target Price from AnalystsJune 7 at 1:41 AM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Moderate Buy" by BrokeragesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has received an average rating of "Moderate Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommeMay 31, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | globenewswire.comVerve Therapeutics Announces Leadership UpdateMay 30, 2024 | globenewswire.comVerve Therapeutics to Participate in Upcoming Investor ConferencesMay 20, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Sets New 12-Month Low at $5.66Verve Therapeutics (NASDAQ:VERV) Reaches New 52-Week Low at $5.66May 17, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. lifted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 11.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,397,604 shares oMay 17, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Down 3.6%Verve Therapeutics (NASDAQ:VERV) Stock Price Down 3.6%May 17, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 17, 2024 | insidertrades.comAndrew D. Ashe Buys 76,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockMay 16, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up Following Insider Buying ActivityVerve Therapeutics (NASDAQ:VERV) Shares Gap Up Following Insider Buying ActivityMay 15, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Andrew D. Ashe Acquires 76,000 SharesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Andrew D. Ashe acquired 76,000 shares of Verve Therapeutics stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $6.26 per share, with a total value of $475,760.00. Following the purchase, the insider now directly owns 342,509 shares of the company's stock, valued at $2,144,106.34. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 11, 2024 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong FinancialsMay 10, 2024 | finance.yahoo.comAnalysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This WeekMay 9, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)May 9, 2024 | markets.businessinsider.comBuy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth PotentialMay 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Verve Therapeutics in a research report on Thursday.May 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Releases Earnings Results, Beats Expectations By $0.11 EPSVerve Therapeutics (NASDAQ:VERV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.11. The firm had revenue of $5.70 million for the quarter, compared to analysts' expectations of $2.11 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative return on equity of 39.33%. The company's revenue was up 305.6% compared to the same quarter last year.May 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3% Following Strong EarningsVerve Therapeutics (NASDAQ:VERV) Trading 6.3% Higher on Better-Than-Expected EarningsMay 9, 2024 | finance.yahoo.comVerve Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amid Progress and Promising PipelineMay 8, 2024 | msn.comVerve Therapeutics GAAP EPS of -$0.59 beats by $0.12, revenue of $5.7M beats by $3.45MMay 8, 2024 | investorplace.comVERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102May 3, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Up 7.8%Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7.8%May 3, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $5.93Verve Therapeutics (NASDAQ:VERV) Hits New 12-Month Low at $5.93April 25, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Hits New 52-Week Low at $6.05Verve Therapeutics (NASDAQ:VERV) Reaches New 52-Week Low at $6.05April 21, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Grows Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Sumitomo Mitsui Trust Holdings Inc. boosted its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 11.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,397,604 shares of the company's stock after buApril 20, 2024 | marketbeat.comFederated Hermes Inc. Purchases 1,448,003 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Federated Hermes Inc. lifted its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,980,372 shares of the company's stock after buying an addiApril 18, 2024 | wsj.comGV’s Newest Life Sciences General Partner Pursues Precision TreatmentsApril 18, 2024 | msn.comVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77April 17, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Down 2.9%Verve Therapeutics (NASDAQ:VERV) Shares Down 2.9%April 15, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $7.26Verve Therapeutics (NASDAQ:VERV) Reaches New 12-Month Low at $7.26April 11, 2024 | benzinga.comTop 3 Health Care Stocks Which Could Rescue Your Portfolio This QuarterApril 9, 2024 | markets.businessinsider.comBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated RecoveryApril 9, 2024 | msn.comA Bold Gene-Editing Solution Began Testing—Then Hit the Strangest TwistApril 8, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Coverage Initiated at HC WainwrightHC Wainwright initiated coverage on shares of Verve Therapeutics in a research report on Monday. They issued a "buy" rating and a $15.00 price objective for the company.April 8, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Stock Position Raised by Vanguard Group Inc.Vanguard Group Inc. lifted its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 18.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,832,968 shares of the company's stock after buying an additional 741,April 6, 2024 | fool.comAfter a Serious Setback, Is Verve Therapeutics a Buy?April 4, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 4.8%Verve Therapeutics (NASDAQ:VERV) Shares Up 4.8%April 4, 2024 | insidertrades.comJoan Nickerson Sells 1,514 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockApril 3, 2024 | msn.comGene Editing Experiment Halted as Patient Gets Weird Side EffectsApril 3, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Joan Nickerson Sells 1,514 SharesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 1,514 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $8.24, for a total value of $12,475.36. Following the completion of the sale, the insider now owns 8,659 shares in the company, valued at $71,350.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.April 3, 2024 | seekingalpha.comVerve Therapeutics: An Update On Human CRISPRApril 3, 2024 | seekingalpha.comVerve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment PauseApril 2, 2024 | msn.comVerve Therapeutics pauses enrollment of patients in trial for its gene therapy to treat high cholesterol after severe side effect Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… VERV Media Mentions By Week VERV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.130.76▲Average Medical News Sentiment VERV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼23▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evotec News Today Protagonist Therapeutics News Today NewAmsterdam Pharma News Today Harmony Biosciences News Today Edgewise Therapeutics News Today Taro Pharmaceutical Industries News Today Syndax Pharmaceuticals News Today Ardelyx News Today Kura Oncology News Today Dynavax Technologies News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredThe Most Dangerous Time for 401k OwnersThe world's most powerful CEO just issued a grave warning to Americans... "This may be the most dangerous t...Birch Gold | Sponsored